EAG Launches New Lab in China for Product Improvement
The new lab will be dedicated to improving materials and electronics using advanced imaging and surface analysis expertise.
EAG Laboratories, a Eurofins company based in San Diego, CA and specializing in scientific services, announced the launch of its new laboratory in Shanghai, China, on Aug. 15, 2019. The new facility will focus on improving materials, products, and electronics while using advanced imaging and surface analysis expertise and providing manufacturers with direct access to scientific expertise in the analysis of physical structures, chemical properties, and composition of materials.
The lab comes equipped with advanced microscopy capabilities in transmission electron microscopy (TEM [FEI Themis Z]), which is capable of ultra-high energy resolution and ultra-high sub-atomic spatial resolution for imaging and chemistry, and dual beam focused ion beam (FIB) (Helios G4 HX and UC FIBs). The new facility also improves the company’s abilities in secondary ion mass spectrometry (SIMS) with the PHI ADEPT 1010 SIMS tool, which is optimized for high-depth resolution analysis of semiconductors, thin films, and bulk insulators.
Source: EAG Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
